Maple Med Global Signs South Korea Stem Cell Partnership

Maple Med Global Founder and CEO Ceylan Adiguzel welcomed Lee Seung Yup, CEO of Konextrip, to the company’s Toronto office for a strategic meeting focused on cord blood stem cell therapy and regulated regenerative medicine programs in South Korea.

Over the past few years, there has been a noticeable increase in inquiries from patients dealing with chronic knee pain, cartilage damage, and degenerative joint conditions such as osteoarthritis. Many are not ready to move forward with surgery, while others are exploring international options in regenerative medicine for knee problems and emerging cartilage regeneration approaches.

South Korea has developed a strong position in biotechnology and advanced cell processing systems. During the meeting, discussions centered on how umbilical cord blood stem cell therapy is structured within clinical settings, the scientific background behind cell proliferation capacity, and current applications being explored in orthopedic and anti-aging regenerative medicine programs.

The meeting concluded with the signing of a formal cooperation protocol between Maple Med Global and Konextrip. Under this agreement, Konextrip will serve as Maple Med Global’s official local representative and operational partner in South Korea. This partnership establishes a structured referral and coordination pathway for North American patients seeking access to South Korea stem cell therapy programs.

With this agreement, Maple Med Global further expands its global medical network while maintaining its established model built on compliance, transparency, and patient-focused coordination. The partnership strengthens direct access to regulated South Korea regenerative medicine programs, particularly in the areas of knee-related stem cell applications and longevity-focused cellular treatments.